Amgen obtains broader patent protection for NEUPOGEN.THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 4, 1996--Amgen (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :AMGN) Wednesday announced that the U.S. Patent and Trademark Office has issued to the company a patent covering product rights to its recombinant G-CSF G-CSF granulocyte colony-stimulating factor. G-CSF granulocyte-colony stimulating factor. G-CSF Granulocyte colony-stimulating factor Molecular therapeutics A biological response modifier, the recombinant DNA form of or NEUPOGEN (R) (Filgrastim). The patent, issued on Dec. 3 as U.S. Patent No. 5,580,755, provides additional protection against unauthorized making, importation, use or sale of recombinant G-CSF in the United States. The patent provides 17 years of such protection. Previous patents cover aspects of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. , vectors and processes related to recombinant G-CSF. "This new patent provides additional, broad patent protection and strengthens our intellectual property position on NEUPOGEN," said Gordon Binder, Amgen's chairman and chief executive officer. NEUPOGEN is licensed in this country by the Food and Drug Administration for the reduction of neutropenia in four indications: as an adjunct to cancer chemotherapy; to support Peripheral Blood Progenitor Cell (PBPC PBPC Peripheral Blood Progenitor Cell PBPC Palm Beach Photographic Centre (Delray Beach, FL) PBPC Pneumatic Back-Up Pressure Control PBPC Pseudo-Random Binary Phased-Code ) transplants; in conjunction with Bone Marrow Transplant bone marrow transplant: see bone marrow. (BMT BMT bone marrow transplantation. BMT, n.pr See bone marrow transplant. BMT Bone marrow transplant, see there ); and in a blood disorder known as Severe Chronic Neutropenia (SCN), in which the marrow fails to manufacture sufficient infection-fighting neutrophils. Nine-month U.S. sales of NEUPOGEN through Sept. 30, 1996 were $534 million. Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. CONTACT: Amgen, Thousand Oaks David Kaye, 805/447-6692 (media) Denise Powell, 805/447-4346 (investors) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion